Clinical trial registry record

Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Unknown.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated February 9, 2011.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT01249937
Last registry update
February 9, 2011
Status
Unknown
Phase
Phase 2
Sponsor
University Health Network, Toronto
Enrollment
30
Countries
Canada
Match confidence
80%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · SINGLE
Evidence population
Human clinical study registration
Participants
30
Population
ALL · 18 Years
Duration
2011-01-01 to 2011-10-01
Intervention
Ranibizumab; Triamcinolone Acetonide
Comparator
Ranibizumab; Ranibizumab and Triamcinolone acetonide
Outcomes measured
Gains in visual acuity — Baseline and months 1, 2, 3, 4, 5, and 6; Changes in intra-ocular pressure — Baseline and months 1, 2, 3, 4, 5 and 6; Rates of re-treatment — Months 1, 2, 3, 4, 5 and 6; Rate of vision loss — Baseline and months 1, 2, 3, 4, 5 and 6; Rate of cataract progression — Baseline and months 1, 2, 3, 4, 5, and 6; • Changes in choroid vessel activity in lesion growth and activity at choroid — Baseline and months 1, 2, 3, 4, 5 and 6
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 80% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 80%Title contains controlled topic terminology. Title supplies ageing or longevity context.

Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON